

IBD HIGHLIGHTS

SGG-SASL-SVEP Annual Congress 2026

INTERLAKEN · 17–18 SEPTEMBER 2026

Thursday, 17 September 2026

INFLAMMATORY BOWEL DISEASE · THEATERSAAL · 08:35–10:00

- 08:35** The IBDome
Sebastian Zeissig, Bern
- 08:56** Urgency and incontinence in IBD
Thomas Greuter, Lugano
- 09:17** Management of postoperative patients with IBD
Alain Schoepfer, Lausanne
- 09:38** Legacy drugs and their place in current IBD treatment
Gerhard Rogler, Zürich

LUNCH SYMPOSIA · 12:15–13:20

- 12:15** Eli Lilly — The patient in front of you: real-world decisions in IBD
S. Zeissig, S. Brand, A. Walsh
- 12:15** Johnson&Johnson — Maintenance Matters: From Dark Matters to Deep Remission
L. Biedermann, P. Michetti
- 12:50** Takeda — IBD in 2026: What's the Verdict beyond Symptom Control?
L. Biedermann, P. Juillerat, S. Restellini

IBD ORAL PRESENTATIONS · THEATERSAAL · 13:30–15:00

- 13:30** When could fecal transplantation be appropriate in IBD?
Michael Scharl, Zürich
- 14:10** Novel anti-integrin $\alpha\text{v}\beta 6$ autoantibodies distinguish UC from Crohn's disease
Samuel Truniger, St. Gallen
- 14:20** Risk of venous thromboembolism in pregnancy/postpartum in women with IBD — Swiss cohort study
Julian Heierle, Basel
- 14:40** Baseline microbial ecology predicts response to D-lactate-free probiotic therapy in colitis
Bahtiyar Yilmaz, Bern
- 14:50** Upadacitinib and symptomatic remission in UC — interim IBD-DACH EUROPE data
Sebastian Zeissig, Bern

IBD: MEET THE EXPERTS · AUDITORIUM · 15:30–17:00

- 15:30** Innovative Therapieansätze bei IBD
Jan Hendrik Niess, Basel
- 15:52** Transition in Theorie und Praxis
Dimitri Rast, Basel
- 16:14** Transition: das Konzept und die Praxis — Herausforderungen
Mary-Louise Daly, Basel
- 16:38** Transition aus Sicht der Patientin / des Patienten
—

GENERAL ASSEMBLY IBDnet

19:00 · Saal Brünig

Friday, 18 September 2026

JOINT SESSION — BEST IN SCIENCE, PRACTICE AND CARE · AUDITORIUM

- 11:40** Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis
Palle Bager, Aarhus, Denmark

LUNCH SYMPOSIUM

- 12:15** AbbVie — Ultrasound-Guided Therapy Decision in IBD: Switch or No-Switch?
T. Greuter, S. Zeissig, S. Restellini

IBD-RELATED POSTERS

Gastroenterology section

- Gastro 1** Peripheral Blood–Associated Microbial Signatures as Predictors of Therapy Response in IBD
V. Dobernig, C. Mamie, Y. Morsy, M. Scharl (USZ Zürich)
- Gastro 8** Sustained improvement in patient-reported outcomes with long-term risankizumab in UC – COMMAND OLE
L. Biedermann et al.
- Gastro 9** Real-world guselkumab outcomes in pre-approval-treated IBD patients with psoriatic comorbidity (SPHERE-IBD)
L. Biedermann, E. Burri, T. Greuter et al.
- Gastro 10** Patient-reported adherence to ECCO guidelines across the DACH region
C. Bodmer, C. Nötel, L. Biedermann et al.
- Gastro 19** Mode-of-delivery preferences in IBD: patients prefer oral, HCPs subcutaneous (CHOOSE)
A. Lehmann, B. Giardina et al.
- Gastro 20** Shared decision-making scores mask preference gaps between IBD patients and HCPs (CHOOSE)
A. Lehmann, B. Giardina et al.
- Gastro 21** Major adverse cardiovascular events during pregnancy/postpartum in women with IBD – Swiss cohort
J. Heierle, C. Eichhorn et al.
- Gastro 22** IBD-Disk: sex-specific disease burden in UC, reduced by upadacitinib – IBD-DACH EUROPE
M. Wiestler, R. Schmelz et al.
- Gastro 25** Guselkumab real-world experience in Switzerland: dose, formulation and patient selection – 72 IBD patients
P. Juillerat et al.
- Gastro 26** Real-world effectiveness and safety of risankizumab in Crohn's disease – APPRISE interim results
P. Bossuyt, T. Hisamatsu et al.

Source: SGG-SASL-SVEP Congress Program 2026